Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency

Publisher： John Wiley & Sons Inc

E-ISSN： 1538-7836|16|2|253-261

ISSN： 1538-7933

Source： JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol.16, Iss.2, 2018-02, pp. : 253-261

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial

By  

TRANSFUSION, Vol. 58, Iss. 2, 2018-02 ,pp. : 413-422

John Wiley & Sons Inc

Access to resources Recommend Favorite

Postauthorization safety study of Clottafact®, a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study

By  

VOX SANGUINIS, Vol. 113, Iss. 2, 2018-02 ,pp. : 120-127

John Wiley & Sons Inc

Access to resources Recommend Favorite

Molecular Basis of Fibrinogen Deficiency

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 35, Iss. 1-2, 2006-06 ,pp. : 187-198

Karger

Access to resources Recommend Favorite

Use of fibrinogen concentrate in bleeding patients

By  

ANAESTHESIA, Vol. 3-2409, Iss. 11, 2015-11 ,pp. : 1323-1324

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of fibrinogen concentrate in bleeding patients

By  

ANAESTHESIA, Vol. 70, Iss. 11, 2015-11 ,pp. : 1323-1324

John Wiley & Sons Inc

Access to resources Recommend Favorite